logo
Products
Services
Resources
Selection Guides
About
PerCP Anti-human CD22 Antibody
HIB22
HIB22 is an anti-human monoclonal antibody that recognizes the CD22 antigen. CD22 (also known as BL-CAM or Lyb8) is a 120 - 130 kD glycoprotein that is located on the surface of cells like B cells and stem cells. CD22 plays a role in essential cellular pathways, namely, the negative regulation of B cell receptor signaling pathway. Moreover, in many organisms, it is a negative regulator of calcium-mediated signaling, suppresses immunoglobulin secretion and is involved in the negative regulation of B cell receptor signaling pathway. From a research standpoint, it is of biological interest due to its association with key macromolecules/ligands like PI3-kinase, PLCg1, p53/56lyn and CD45. CD22 is a fairly uncommon antibody target, with a little more than 4000 publications in the last decade. Even still, CD22 is vital to cell biology research, frequently serving as a phenotypic marker for differentiating cell types in flow cytometric applications. This antibody was purified through affinity chromatography and conjugated to PerCP (ex/em = 477/678 nm). It is compatible with the 488 nm laser and 667/30 nm bandpass filter (for example, as in the Agilent Technologies NovoCyte Advanteon).
product image
product image
CatalogSize
Price
Quantity
102201T025 tests
Price
102201T1100 tests
Price
102201T2500 tests
Price
 
Antibody properties

Other namesBL-CAM, Siglec-2
CloneHIB22
HostMouse
IsotypeIgG1
ReactivityHuman
Spectral properties

Correction factor (280 nm)0.22
Extinction coefficient (cm -1 M -1)
406000
Excitation (nm)477
Emission (nm)678
Storage, safety and handling

H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on April 8, 2026